JNCCN Special Edition Supplement: Metastatic Colorectal Cancer

In this special issue of JNCCN, multiple articles integrate a spectrum of treatment approaches, strategies, and challenges, reflecting comprehensive care for patients with metastatic colorectal cancer. First, the case report by colorectal cancer experts at the City of Hope Comprehensive Cancer Center provides a multidisciplinary review of the optimal management of the patient with synchronous metastatic rectal cancer, often the topic of considerable debate at tumor boards around the country. The emphasis on multidisciplinary collaboration and coordination is critical for the care of these individuals, as is highlighted in this case report and discussion.

An article from Drs. Ciombor and Bekaii-Saab at The Ohio State University Comprehensive Cancer Center summarizes the array of treatment opportunities for patients with metastatic colorectal cancer. This article also addresses future research opportunities to tackle unanswered questions. Dr. Grem, from the University of Nebraska Medical Center, discusses sequencing of treatment in advanced unresectable disease, with an emphasis on achieving the balance between efficacy and toxicity and the management strategies required.

Finally, Drs.Vergo and Cullinan from the Section of Palliative Care at Dartmouth-Hitchcock Medical Center discuss the growing emphasis on the early introduction of palliative care for patients with advanced disease, and offer their insights on focusing on the symptoms, social, spiritual, and emotional needs of our patients, and when primary palliative care may be insufficient and referral to specialty palliative care is recommended. Our inability to cure most patients with metastatic colorectal cancer warrants attention to the importance of integrating specialty palliative care as an essential strategy.

Intended Audience
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Accreditation
These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits may also be provided. Please refer to the complete accreditation information provided before each individual educational activity for more details.

Fee Information
There is no fee for these activities.

Supporters
Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc.; Genentech, USA; Lilly USA, LLC; and sanofi-aventis U.S. and Regeneron Pharmaceuticals

Course summary
Course opens: 
10/04/2013
Course expires: 
08/31/2014
Cost:
$0.00

Available Credit

Accreditation Period

Course opens: 
10/04/2013
Course expires: 
08/31/2014
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.